Buy-the-Dip Setup in Novartis: Synnovation Deal and Durable Growth Make $NVS a Tactical Long
Novartis's $3B Synnovation deal for SNV4818, fresh pediatric approvals for Cosentyx, and visibility into mid-single-digit growth create a tangible earnings and revenue catalyst profile. The shares are trading off recent highs and show oversold technicals, setting up a mid-term long trade with defined risk management.